CD4 and colitis: Therefore, we decided to examine whether MLN CD25+CD4+ T cells from DSS-treated Yeti/CD1d KO mice (mostly Foxp3− populations) can increase susceptibility to DSS-induced colitis compared to CD25+CD4+ T cells (primarily Foxp3+ populations) from DSS-treated CD1d KO mice.